160 HEALTH (02656): Backed by Both Barclays and Southbound Capital, Is the Inflection Point for Large-Scale Commercialization of AI Healthcare Near?

On October 29, shares of 160 HEALTH (02656) showed significant movement. The stock rose as much as 37.42% within the first hour of morning trading, extended its maximum gain to 57.51% in the afternoon session, and ultimately closed up 45.88%. The reason lies in Barclays PLC increasing its stake in the company on that day by 24.182 million shares at an average price of HK$3.18 per share, involving approximately HK$76.9278 million. The positive bellwether action by an international investment bank attracted many market funds to follow suit and turn bullish, giving 160 HEALTH a long-awaited rally. From breakout to shrinking-volume pullback, where will the share price go? Affected by the lock-up expiry wave in September this year combined with shareholder reductions, 160 HEALTH's share price retreated noticeably in September and October. It is not difficult to see from the trading action that during this period the market, almost solely on the single logic of "reduction equals negative," pressed the share price from around HK$7.5 before the lock-up expiry all the way down to the HK$2 range in the second half of October. It was observed that on October 7, 160 HEALTH's trading volume shrank extremely to 146,800 shares; afterward the share price continued to fluctuate slightly downward. On October 14, despite the share price closing down only 1.91%, single-day volume reached 54.8175 million shares, marking a round of concentrated release of on-market selling pressure during the lock-up expiry window. Evidently, before Barclays' stake disclosure, the exhaustion of sell orders in 160 HEALTH was traceable. On October 27, 160 HEALTH's share price touched an intraday low of HK$2.10, and single-day volume shrank again from prior highs to less than 8 million shares, meaning most of the overhead chips had been cleared out. The chip distribution that day showed that 160 HEALTH's on-market chips were mainly concentrated near the HK$2.14 support level, with the chip peak price far below the average holding cost of HK$6.52. Such a chip structure gave Barclays a relatively good entry timing. Although Barclays ultimately chose to enter at this time node at a transaction price of HK$3.18, nearly 50% above the support level, because 160 HEALTH's share price was at a persistently low level, it could still obtain a considerable risk-reward ratio. Judging from the trading action after Barclays' stake disclosure, following the breakout on October 29, 160 HEALTH's share price began a period of obvious high-level divergence the next day. From October 30 to November 3, its intraday turnover rate fell from 34.5% to 16.5% and then rebounded to 24.9%, with corresponding share price amplitude reaching 15-25%, indicating intense bullish-bearish turnover on the market during this period, with profit-taking outflows and new incoming funds absorbing shares simultaneously. After the first round of full chip exchange ended, 160 HEALTH's rally was clearly not over. From November 4 to 6, the company's share price made a second attempt to push higher in this rally. On November 6, 160 HEALTH's intraday gain reached as high as 21.92% and closed up 12.96%, with the day's turnover rate reaching 46.81% and daily volume reaching 163 million shares. However, while OBV peaked simultaneously that day, 160 HEALTH's second attempt to test the top did not drive single-day volume to a new high, and its performance remained below the October 29 peak. With the confirmation of the short-term "double top" structure, 160 HEALTH's share price saw a sustained shrinking-volume decline from November 9 to November 13, with average daily volume contracting more than 50% from the prior high. Combining technical indicators, the recent "five consecutive bearish candles" pushed 160 HEALTH's share price below the 5-day and 10-day moving averages, showing short-term pressure signals, but its 20-day moving average and SARtwo medium-term trend lineshave not been breached, and the RSI14 indicator remains in the relatively strong zone above 50. Therefore, at this point 160 HEALTH is still in a relatively healthy short-term pullback phase; even though on November 12 it saw single-day volume exceeding 40 million shares and closed down 7.41%, it did not break the confidence of bulls on the market. On November 3, the company's single-day volume shrank again, and sell orders continued to dry up. This usually indicates that the share price decline at this time was more constrained by liquidity factors rather than active on-market selling pressure. Under this trend, if the share price subsequently stabilizes with continued shrinking volume near the 20-day moving average and shows an upward trend, it is expected to start a new round of stabilization and rebound. Southbound capital continues to increase holdings, betting on the inflection point of AI healthcare commercialization On March 31 this year, the National Healthcare Security Administration officially included 12 AI-assisted diagnostic items in the national unified Class B medical insurance catalog and implemented them simultaneously in 837 tertiary hospitals nationwide, making China the first country in the world to include AI diagnostics on a large scale in the national medical insurance system. This breakthrough on the medical insurance payment side opened the "last mile" of AI healthcare commercialization, and the industry generally believes it will significantly accelerate products from R&D to routine clinical use. In fact, this is just one microcosm of the accelerated implementation of policy support for AI healthcare commercialization in China. It is understood that as early as last October, the National Health Commission and four other departments jointly issued the "Implementation Opinions on Promoting and Regulating the Development of 'AI + Healthcare' Applications," which clearly set out the timetable of widespread application of grassroots AI assistance by 2027 and basically full coverage by 2030. This also means that domestic policy support for AI healthcare commercialization has upgraded from "directional statements" to "clear timetable + opening payment channels + setting assessment milestones," making this concept an investment theme with higher certainty. Returning to 160 HEALTH, its uniqueness lies in the fact that the company's business simultaneously captures three core links: hospital-side entry points, AI operation profit sharing, and computing power infrastructure delivery. With continued policy support in China, the monetization rate of the above multiple links continues to rise, making 160 HEALTH an eligible target under the AI healthcare commercialization theme. On fundamentals, 160 HEALTH's 26H1 financial report showed that revenue for the period grew 9.7% year-on-year to RMB319 million, and net profit attributable to shareholders reached RMB2.137 million, a sharp year-on-year increase of 111.18%. Compared horizontally with A-share peers Shanghai Runda Medical Technology and Guangzhou LBP Medicine Science & Technology, 160 HEALTH has already achieved an overall turnaround and was the first to show a fundamental inflection point. On September 16, 160 HEALTH issued an announcement declaring that its indirectly wholly-owned subsidiary signed a strategic cooperation framework agreement with a Shenzhen enterprise-level computing power infrastructure service provider, with an estimated total cooperation amount of RMB650 million. On October 13, the company announced that the first sales contract under the framework, worth RMB42 million, was officially implemented. In fact, 160 HEALTH's first AI computing power order of RMB42 million accounts for only 6.4% of its prior full-year revenue, but it still represents the transition of the company's digital healthcare solutions businesswith gross margin exceeding 80%from computing power infrastructure to the realization stage. The subsequent "cross-validation"-style positioning by Barclays and southbound capital at low share prices has become the strongest external signal for this rally. It was observed that after 160 HEALTH disclosed the announcement on September 16, southbound capital made net purchases of 17.799 million shares in the company over four trading days from September 17 to September 22, including 15.581 million shares bought on September 22 alone, pushing the overall shareholding ratio up from 11.34% to 13.88%. Broker trading data over the past 20 days showed that the top five net buyers of 160 HEALTH were Stock Connect (Shanghai), Stock Connect (Shenzhen), CMB Wing Lung Bank, HAITONG INT'L, and The Hongkong and Shanghai Banking Corporation, with net purchases of 16.6728 million shares, 6.1103 million shares, 5.7355 million shares, 3.8253 million shares, and 3.0377 million shares, respectively. It can be seen that the net purchases through the two Stock Connect channels accounted for 64.39% of the top five buyers' total over the past 20 days. In fact, during this period southbound capital has continuously been bargain-hunting in 160 HEALTH against the trend, basically following a left-side trading strategy of "adding positions during sharp declines and pullbacks, and reducing holdings when the rise is too fast." As of November 12, its shareholding ratio in 160 HEALTH had reached 22.47%. In terms of holding cost, southbound capital's weighted estimated average cost since September 16 is approximately HK$3.9, while Barclays' entry price was its stake disclosure price of HK$3.18. The average entry costs of these two channels are clearly above 160 HEALTH's current share price. However, the reference value of these two channels' entry costs lies in providing a pricing anchor from an external perspective. And this pricing anchor is precisely the possibility of 160 HEALTH's digital healthcare business gross margin continuing to climb, as well as the expectation that computing power orders will move from framework to large-scale delivery.